Abstract: A cable and system for manufacturing the same is provided. The cable includes a core communications medium and an outer jacket surrounding the core communications medium. A plurality of grooves are in the outer surface of the outer jacket. Each of the grooves has a recess and an opening to access the recess, the recess having a larger width than the opening. Each of the plurality of conductors is exposed to the external environment and can be reached directly from the external environment.

Abstract: Selective MMP-13 inhibitors are isophthalic acid derivatives of the formula wherein: R1, R2, and R3 independently are hydrogen, halo, hydroxy, C1–C6 alkyl, C1–C6 alkoxy, C2–C6 alkenyl, C2–C6 alkynyl, NO2, NR4R5, CN, or CF3; E is independently O or S; A and B independently are OR4 or NR4R5; each R4 and R5 independently are H, C1–C6 alkyl, C2–C6 alkenyl, C2–C6 alkynyl, (CH2)n aryl, (CH2)n cycloalkyl, (CH2)n heteroaryl, or R4 and R5 when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring, optionally containing a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted; n is 0 to 6; or a pharmaceutically acceptable salt thereof. The compounds are useful for treating diseases in a mammal that are mediated by MMP enzymes.

Abstract: Selective MMP-13 inhibitors are isophthalic acid derivatives of the formula wherein: R1, R2, and R3 independently are hydrogen, halo, hydroxy, C1–C6 alkyl, C1–C6 alkoxy, C2–C6 alkenyl, C2–C6 alkynyl, NO2, NR4R5, CN, or CF3; E is independently O or S; A and B independently are OR4 or NR4R5; each R4 and R5 independently are H, C1–C6 alkyl, C2–C6 alkenyl, C2–C6 alkynyl, (CH2)n aryl, (CH2)n cycloalkyl, (CH2)n heteroaryl, or R4 and R5 when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring, optionally containing a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted; n is 0 to 6; or a pharmaceutically acceptable salt thereof. The compounds are useful for treating diseases in a mammal that are mediated by MMP enzymes.

Abstract: The present invention is a method for identifying a compound as a competitive, noncompetitive, or uncompetitive inhibitor of an enzyme having a functional metal cation, the method comprising assaying the compound for inhibition of the enzyme in the presence of a ligand to the functional metal cation.

Abstract: Selective MMP-13 inhibitors are isophthalic acid derivatives of the formula 1

Abstract: Neurodegenerative disorders, i.e., Alzheimer's disease, stroke, multiple sclerosis and head trauma are treated with 5-??{3,5-bis(1,1,-dimethylethyl)-4-hydroxyphenyl!methylene!-2-imino-4-thia zolidinone or a pharmaceutically acceptable salt thereof.